SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4849-4856. Prepublished online as a Blood First Edition Paper on February 21, 2006; DOI 10.1182/blood-2005-10-4154. This Article Full Text (PDF) All Versions of this Article: 2005-10-4154v1 107/12/4849    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schenten, D. Articles by Rajewsky, K. Search for Related Content PubMed PubMed Citation Articles by Schenten, D. Articles by Rajewsky, K. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 19, 2005 Accepted February 10, 2006 M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B cell lymphomas, is dispensable for the GC reaction in mice Dominik Schenten, Angela Egert, Manolis Pasparakis, and Klaus Rajewsky* The CBR Institute for Biomedical Research and Harvard Medical School, Boston, MA, USA; Institute for Genetics, University of Cologne, Cologne, Germany Institute for Genetics, University of Cologne, Cologne, Germany; EMBL Mouse Biology Unit, Monterotondo-Scalo, Italy * Corresponding author; email: rajewsky{at}cbr.med.harvard.edu. In T cell-dependent antibody responses, antigen-specific B cells undergo a phase of secondary antibody diversification in germinal centers (GCs). Somatic hypermutation (SHM) introduces mutations into the rearranged immunoglobulin (Ig) variable (V) region genes and class switch recombination (CSR) alters the Ig heavy (H) chain constant region. Aberrant SHM or CSR are thought to contribute to the development of GC-derived B cell malignancies. Diffuse large B cell lymphomas (DLBCL) are a heterogeneous group of such GC-derived tumors. Based on their gene expression profile, DLBCL can be divided into activated B cell-like and GC-like subgroups. The human gene HGAL is predominantly expressed in GCs. It is also part of the gene expression signature of GC-like DLBCL and its high expression in DLBCL has been associated with a better clinical prognosis. We have generated mice deficient of the HGAL homologue M17 in order to investigate its functional significance. The mutant animals form normal GCs, undergo efficient CSR and SHM, and mount T cell-dependent antibody responses similar to wild-type controls. Thus, M17 is dispensable for the GC reaction and its potential function in the pathogenesis of DLBCL remains elusive. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: X. Lu, J. Chen, R. Malumbres, E. Cubedo Gil, D. M. Helfman, and I. S. Lossos HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration Blood, December 15, 2007; 110(13): 4268 - 4277. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020